A Generic Drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. Though generic drugs contain the same active ingredients as the brand name counterparts, they are typically less expensive than brand name drugs. Generic drugs become available once brand name drug patents expire.
How are Generic Drugs Developed and Approved?
To gain approval for a Generic Drugs a pharmaceutical company must demonstrate that their Generic Drug is identical to the brand name drug in dosage form, purity, safety, strength, and intended use. Generic Drug makers have to show that the Generic Drug is absorbed by the body in the same way and at the same rate as the brand name drug. Due to these strict requirements, generic drugs are just as safe and effective as brand name drugs.
The approval process for a Generic Drug involves several steps:
Biopharmaceutics Testing: Tests are conducted to ensure the Generic Drug behaves in the same manner as the brand name drug in the body. This involves assessing how quickly and how much of the drug gets absorbed.
Bioequivalence Testing: Studies are done to demonstrate the Generic Drug provides the same concentrations of the active ingredients in the bloodstream as the brand name drug over the same period.
Consumer Testing: Some generic drugs undergo consumer testing to show consumers cannot tell the difference between the generic and brand name versions in characteristics like appearance, taste, and packaging.
Manufacturing Inspections: The FDA inspects Generic Drug manufacturing sites to ensure compliance with good manufacturing practices and purity standards.
Labeling Review: Labels are reviewed to ensure they contain the same safety and dosing information as the brand name drug.
Only after passing all these tests can a Generic Drug obtain FDA approval for marketing and sale in the United States. The extensive testing helps ensure generic drugs deliver the same clinical benefit as brand name drugs.
Cost Savings of Generic Drugs
Generic drugs offer huge savings over brand name drugs. On average, the cost of a Generic Drug is 80-85% less than the brand name version. There are several factors contributing to the lower costs of generic drugs:
- Research and Development Costs: Brand name pharmaceutical companies incur huge costs for research, clinical trials, marketing, and patenting new drugs. Generic makers do not face these substantial research costs.
- Manufacturing Costs: Once competition enters the market after patent expiry, manufacturing costs decrease significantly due to economies of scale. This drives down the prices of generic drugs.
- No Marketing Costs: Generic makers do not engage in large marketing campaigns like brand name companies. This eliminates a major cost component.
- Price Competition: When multiple generic versions of a drug enter the market, competition intensifies and drives prices down rapidly. Low Generic Drug prices have significantly reduced prescription drug costs for consumers.
However, it is important to note the cost savings on generics are only possible because of the enormous investments made by brand name companies for drug innovation. Strict FDA regulations also help ensure generic drugs deliver the same clinical outcomes as brand drugs.
Are Generic Drugs as Safe and Effective as Brand Name Drugs?
FDA approval requirements mean generic drugs are just as safe and effective as their brand name counterparts. Generic drugs contain the same active ingredients as brand drugs and function identically in the body. Strict bioequivalence testing verifies generic drugs provide an equivalent therapeutic effect. Additionally, generic drugs undergo the same rigorous manufacturing standards as brand drugs to ensure quality and purity.
Manufacturers of both brand name and generic drugs are also subject to regular facility inspections by FDA to ensure continued adherence to good manufacturing practices. Post-marketing safety monitoring helps identify any rare adverse effects of both generics and brands.
The only difference between generic and brand drugs is their manufacturing source and cost, not their safety or effectiveness profile. Numerous scientific studies also confirm generic substitution poses no greater safety risks than continued use of the same brand drug. Overall, generic drugs deliver the same clinical outcomes as their brand counterparts at a much lower price point.
The success of generic drugs in delivering massive cost savings has been one of the most impactful developments for healthcare affordability. By providing interchangeable alternatives to expensive brand drugs, generics have saved the U.S. healthcare system billions annually. With prescription drug costs rising rapidly, generic drugs will continue playing an important role in curbing medicinal expenses for patients, insurers, and taxpayers alike. Whenever possible and clinically appropriate, opting for generic versions remains a smart choice for both individual budgets and the sustainability of our healthcare system overall.
Get This Report In Japanese
Get This Report In Korean
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
The global overactive bladder treatment market is projected to reach USD 4.19 Billion by 2022 from USD 3.63 Billion in 2017, at a CAGR of 2.9% during the forecast period.
This market is consolidated in nature with a few regional and national players.
In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (U.S.) dominated the overactive bladder treatment market and accounted for approximately 60% to 70% share of the overall market Astellas Pharma, Inc. dominated the global overactive bladder treatment market in 2016.
The company offers two patented drugs, namely, VESIcare (solifenacin) and BETMIGA (mirabegron) in the market.
Astellas’ “Creating Innovation” strategy, backed by its R wing, helps identify new therapeutic areas as well as new solutions for existing areas.
As of April 2017, Astellas has 47 molecular and biological entities in the clinical pipeline.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=219938791Pfizer, Inc. held the second position in the global overactive bladder treatment market in 2016.
